Want to see BBIO full AI Analyst Report?
Top Page
BridgeBio Pharma
(NASDAQ:BBIO)
Select Model
Select Model
Rating:62Neutral
Price Target:
$88.00
▲(4.74% Upside)
Action:Reiterated
Date:07/23/26
BBIO scores as a balanced risk/reward setup: the biggest drag is weak financial performance (large losses, cash burn, and negative equity), while the most supportive factors are strong earnings-call signals (rapid Atruvio growth, sizeable cash, and breakeven/cash-flow-positivity targets) and constructive technical momentum. Valuation is constrained by negative earnings, and recent corporate events are broadly supportive due to key FDA milestones and strengthened capital.
Positive Factors
Rapid Atruvio revenue growth
Sustained, large QoQ and YoY Atruvio growth demonstrates durable commercial traction and expanding patient uptake. This revenue base can fund scale, enable operating leverage as fixed costs are spread, and underpins management's path to breakeven while supporting launches of additional pipeline assets.
Negative Factors
Large ongoing cash burn and negative FCF
Persistent negative operating and free cash flow indicate the business remains cash‑consumptive absent sustained commercial scale. Continued burn elevates dependency on external financing, risks dilution, and constrains discretionary investment if revenues slow or launch costs run higher than planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Atruvio revenue growth
Sustained, large QoQ and YoY Atruvio growth demonstrates durable commercial traction and expanding patient uptake. This revenue base can fund scale, enable operating leverage as fixed costs are spread, and underpins management's path to breakeven while supporting launches of additional pipeline assets.
Read all positive factors
BridgeBio Pharma Key Performance Indicators (KPIs)
Any
Revenue by Segment
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Highlights how much revenue each business segment generates, providing insight into which areas are driving growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBridgeBio Pharma (BBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.38B
Dividend YieldN/A
Average Volume (3M)4.02M
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue Growth355.17%
EPS Growth-6.09%
CountryUS
Employees839
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.75
Shares Outstanding196,036,790
10 Day Avg. Volume2,133,765
30 Day Avg. Volume4,019,845
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$107.39Price Target Upside27.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$961.37M
BridgeBio Pharma Business Overview & Revenue Model
Company Description
BridgeBio Pharma, Inc. (BBIO) is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for genetic diseases and cancers. The company operates through a portfolio model, advancing multiple drug programs sp...
How the Company Makes Money
BridgeBio makes money primarily through (1) product sales from its commercial medicines and (2) collaboration-related income typical of biopharma companies.
1) Product sales (commercial revenue)
- BridgeBio generates revenue from the sale of its ...
BridgeBio Pharma Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong commercial momentum (notably Atruvio revenue growth: $180.6M, +24% QoQ, +392% YoY), robust cash runway ($940.2M) and clear pipeline progress with active launch preparations (LGMD2I NDA, ADH1 patient ID, positive PROPEL‑3 for achondroplasia). Management emphasized clinical differentiation backed by real‑world evidence and favorable long‑term economics, while acknowledging short‑term expense pressures (operating expenses +$72.1M) and an operating loss of $106M that should narrow later in the year. Competitive risks, diagnostic supply issues, and the prior‑year milestone timing created some near‑term revenue volatility, but overall the company presented multiple tangible positives that outweigh the listed challenges.Positive Updates
Atruvio Net Product Revenue Surge
Atruvio U.S. net product revenue of $180.6 million in Q1 2026, representing 24% quarter‑over‑quarter growth and 392% year‑over‑year growth; company describes brand as becoming a 2026 blockbuster with growing frontline share and >6,100 total new patient starts in the category this quarter.
Negative Updates
Sharp Decline in License & Services Revenue
License and services revenue fell to $0.4 million from $79.7 million year‑over‑year, reflecting the absence of a one‑time $75 million regulatory milestone recognized in the prior year; causes a revenue mix swing and volatility in reported top line.
Read all updates
Q1-2026 Updates
Positive
Negative
Atruvio Net Product Revenue Surge
Atruvio U.S. net product revenue of $180.6 million in Q1 2026, representing 24% quarter‑over‑quarter growth and 392% year‑over‑year growth; company describes brand as becoming a 2026 blockbuster with growing frontline share and >6,100 total new patient starts in the category this quarter.
Read all positive updates
Company Guidance
Management’s guidance emphasized continued Atruvio-driven growth and improving financial durability: Q1 total revenue was $194.5M (vs. $116.6M YoY) led by Atruvio U.S. net product revenue of $180.6M (24% q/q, +392% YoY), a $143.9M Atruvio lift that contributed to a $77.9M revenue increase overall; royalty revenue rose to $9.5M while license/services fell to $0.4M (prior-year $79.7M). They reported total operating expenses of $290.5M (SG&A $163.9M, +$57.5M; R&D $126.6M, +$15.2M), a $106M operating loss (but losses have narrowed >50% over five quarters), and $940.2M in cash and marketable securities (up from $587.5M), with guidance that losses should flatten over the next two quarters and the company expects to reach P&L breakeven and then sustainable cash-flow positivity by year‑end; the board also authorized a $500M share‑repurchase program to start immediately. Operational and pipeline metrics cited to support commercial outlook included >6,100 new patient starts in the ATTR class this quarter, a projected $4B peak for Atruvio, an IP runway of at least six years, real‑world signals such as a 43% reduction in diuretic intensification vs. tafamidis and Phase III OLE month‑54 mortality reductions (all‑cause −45%, CV −49%, p<0.0001), ~500 genetically confirmed LGMD2I U.S. patients, ~2,000 ADH1 patients identifiable via claims, achondroplasia unaided awareness >40%, and infigratinib’s 2.1 cm annualized height‑velocity benefit.BridgeBio Pharma Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 579.96M | 502.08M | 221.90M | 9.30M | 77.65M | 69.72M |
| Gross Profit | 543.90M | 473.81M | 218.02M | 6.86M | 74.21M | 66.60M |
| EBITDA | -608.84M | -672.88M | -436.83M | -565.47M | -397.44M | -533.83M |
| Net Income | -725.93M | -729.31M | -535.76M | -643.20M | -481.18M | -562.54M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 936.02M | 919.34M | 546.38M | 623.04M | 1.01B |
| Cash, Cash Equivalents and Short-Term Investments | 940.19M | 587.48M | 681.10M | 434.88M | 471.92M | 836.66M |
| Total Debt | 3.38B | 2.73B | 1.73B | 1.74B | 1.72B | 1.73B |
| Total Liabilities | 3.64B | 3.01B | 2.38B | 1.89B | 1.87B | 1.88B |
| Stockholders Equity | -2.27B | -2.08B | -1.47B | -1.35B | -1.25B | -870.41M |
Cash Flow | ||||||
| Free Cash Flow | -454.12M | -447.01M | -521.66M | -529.03M | -425.81M | -546.18M |
| Operating Cash Flow | -443.95M | -445.91M | -520.73M | -527.72M | -419.49M | -497.93M |
| Investing Cash Flow | -65.03M | -24.49M | 60.78M | 54.03M | 453.15M | -200.83M |
| Financing Cash Flow | 848.26M | 359.29M | 748.46M | 451.54M | -13.13M | 736.45M |
BridgeBio Pharma Technical Analysis
Neutral
84.02
Price Trends
74.12
Positive
72.74
Positive
71.38
Positive
Market Momentum
3.21
Positive
64.15
Neutral
57.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Neutral. The current price of 84.02 is above the 20-day moving average (MA) of 82.49, above the 50-day MA of 74.12, and above the 200-day MA of 71.38, indicating a neutral trend. The MACD of 3.21 indicates Positive momentum. The RSI at 64.15 is Neutral, neither overbought nor oversold. The STOCH value of 57.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BBIO.
BridgeBio Pharma Risk Analysis
BridgeBio Pharma disclosed 101 risk factors in its most recent earnings report. BridgeBio Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | $13.91B | 18.11 | 40.21% | ― | 3.33% | 38.64% | |
71 Outperform | $11.86B | 44.34 | 4.41% | ― | 12.53% | -49.09% | |
62 Neutral | $16.38B | -22.81 | 36.00% | ― | 355.17% | -6.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.62B | -6.85 | -36.73% | ― | -29.97% | 6.60% | |
50 Neutral | $8.93B | -27.79 | -110.84% | ― | -7.49% | -98.12% | |
46 Neutral | $12.61B | -42.09 | -56.65% | ― | 256.82% | 29.06% |
* Healthcare Sector Average
BBIO
BridgeBio Pharma
80.09
32.72
69.07%
BMRN
BioMarin Pharmaceutical
60.02
1.88
3.23%
EXEL
Exelixis
53.03
15.77
42.32%
IONS
Ionis Pharmaceuticals
51.77
8.74
20.31%
MDGL
Madrigal Pharmaceuticals
467.32
165.15
54.65%
MRNA
Moderna
54.82
27.22
98.59%
BridgeBio Pharma Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio’s Encaleret NDA Accepted by U.S. FDA
Positive
Jul 22, 2026
On July 22, 2026, BridgeBio announced that the U.S. Food and Drug Administration accepted its New Drug Application for encaleret to treat autosomal dominant hypocalcemia type 1, assigning a Prescription Drug User Fee Act target action date of May ...
Business Operations and StrategyPrivate Placements and Financing
BridgeBio Raises $934 Million via Preferred Equity Financing
Positive
Jul 2, 2026
On July 1, 2026, BridgeBio Pharma entered into an investment agreement with funds managed by Sixth Street and HealthCare Royalty for a $933.9 million issuance of Series A Cumulative Convertible Participating Preferred Stock, with Sixth Street cont...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
BridgeBio shareholders approve board changes and equity plan
Positive
Jun 26, 2026
On June 22, 2026, BridgeBio Pharma held its annual meeting of stockholders, at which director Randal W. Scott resigned from the board upon completion of his term as a Class I director, with the company stating his departure did not stem from any d...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio Wins FDA Priority Review for BBP-418 Therapy
Positive
May 27, 2026
On May 27, 2026, BridgeBio Pharma announced that the U.S. Food and Drug Administration accepted and granted Priority Review to its New Drug Application for oral BBP-418 to treat limb-girdle muscular dystrophy type 2I/R9, with a Prescription Drug U...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
BridgeBio Files FDA NDA for Encaleret in ADH1
Positive
May 13, 2026
On May 12, 2026, BridgeBio Pharma announced it had submitted a New Drug Application to the U.S. Food and Drug Administration for encaleret as a targeted treatment for autosomal dominant hypocalcemia type 1, following positive Phase 3 CALIBRATE res...
Private Placements and FinancingRegulatory Filings and Compliance
BridgeBio Pharma Launches New $500 Million ATM Program
Neutral
May 8, 2026
On May 7, 2026, BridgeBio Pharma, Inc. filed an automatic shelf registration statement on Form S-3ASR with the U.S. Securities and Exchange Commission and entered into a new Equity Distribution Agreement with Goldman Sachs Co. LLC and Leerink Par...
Business Operations and StrategyStock BuybackFinancial Disclosures
BridgeBio Pharma Announces $500 Million Stock Repurchase Program
Positive
May 7, 2026
BridgeBio reported first-quarter 2026 revenue of $194.5 million, largely driven by $180.6 million in U.S. Attruby sales, alongside expanding real-world evidence showing significant mortality and quality-of-life benefits versus existing therapies, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.